Literature DB >> 33472892

Survivin Expression Is Differentially Regulated by a Selective Cross-talk between RBM38 and miRNAs let-7b or miR-203a.

Christopher A Lucchesi1, Jin Zhang1, Buyong Ma2,3, Ruth Nussinov2, Xinbin Chen4.   

Abstract

RNA-binding motif 38 (RBM38) is a member of a protein family with a highly conserved RNA-binding motif and has been shown to regulate mRNA processing, stability, and translation. Survivin is an essential modulator of apoptotic and nonapoptotic cell death as well as a stress responder. Survivin mRNA is the fourth most frequently overexpressed transcript in the human cancer transcriptome, and its aberrant expression is associated with chemo-/radioresistance and poor prognosis. In this study, we examined whether survivin expression is regulated by RBM38. RBM38 bound to survivin 3'-untranslated region and suppressed miRNA let-7b from binding to and degrading survivin mRNA, leading to increased survivin expression. RBM38 interacted with argonaute-2 (AGO2) and facilitated miR-203a-mediated degradation of survivin mRNA, leading to decreased survivin expression. Due to the abundance of let-7b over miR-203a, RBM38 ultimately increased survivin expression in HCT116 and MCF7 cells. In addition, Ser-195 in RBM38 interacted with Glu-73/-76 in AGO2, and Pep8, an eight-amino acid peptide spanning the region of Ser-195 in RBM38, blocked the RBM38-AGO2 interaction and inhibited miR-203a-mediated mRNA degradation, leading to enhanced survivin expression. Furthermore, Pep8 cooperated with YM155, an inhibitor of survivin, to suppress tumor spheroid growth and viability. Pep8 sensitized tumor cells to YM155-induced DNA damage in an RBM38-dependent manner. Together, our data indicate that RBM38 is a dual regulator of survivin and that Pep8/YM155 may be therapeutically explored for tumor suppression. SIGNIFICANCE: These findings show that RBM38 exerts opposing effects on survivin expression via two miRNAs, and disruption of the RBM38-AGO2 complex by an eight-amino acid peptide sensitizes tumor spheroids to survivin inhibitor YM155. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33472892      PMCID: PMC8137528          DOI: 10.1158/0008-5472.CAN-20-3157

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  47 in total

1.  Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas.

Authors:  Jin Zhang; Seong-Jun Cho; Limin Shu; Wensheng Yan; Teri Guerrero; Michael Kent; Katherine Skorupski; Hongwu Chen; Xinbin Chen
Journal:  Genes Dev       Date:  2011-07-15       Impact factor: 11.361

2.  Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression.

Authors:  B Carvalho; C Postma; S Mongera; E Hopmans; S Diskin; M A van de Wiel; W van Criekinge; O Thas; A Matthäi; M A Cuesta; J S Terhaar Sive Droste; M Craanen; E Schröck; B Ylstra; G A Meijer
Journal:  Gut       Date:  2008-10-01       Impact factor: 23.059

3.  miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma.

Authors:  Yarui Diao; Xing Guo; Lei Jiang; Gang Wang; Chao Zhang; Jun Wan; Yan Jin; Zhenguo Wu
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

4.  The structure of human argonaute-2 in complex with miR-20a.

Authors:  Elad Elkayam; Claus-D Kuhn; Ante Tocilj; Astrid D Haase; Emily M Greene; Gregory J Hannon; Leemor Joshua-Tor
Journal:  Cell       Date:  2012-06-07       Impact factor: 41.582

5.  Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding.

Authors:  Aleksandra Helwak; Grzegorz Kudla; Tatiana Dudnakova; David Tollervey
Journal:  Cell       Date:  2013-04-25       Impact factor: 41.582

6.  The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response.

Authors:  Trevor G Glaros; Luke H Stockwin; Michael E Mullendore; Brian Smith; Bethanie L Morrison; Dianne L Newton
Journal:  Cancer Chemother Pharmacol       Date:  2012-04-21       Impact factor: 3.288

Review 7.  Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer.

Authors:  Evgeny Chirshev; Kerby C Oberg; Yevgeniya J Ioffe; Juli J Unternaehrer
Journal:  Clin Transl Med       Date:  2019-08-28

Review 8.  Argonaute 2: A Novel Rising Star in Cancer Research.

Authors:  ZhenLong Ye; HuaJun Jin; QiJun Qian
Journal:  J Cancer       Date:  2015-07-16       Impact factor: 4.207

Review 9.  Molecular mechanisms of etoposide.

Authors:  Alessandra Montecucco; Francesca Zanetta; Giuseppe Biamonti
Journal:  EXCLI J       Date:  2015-01-19       Impact factor: 4.068

10.  miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1.

Authors:  Yi Zhang; Shu-yan Zhou; Hai-zhao Yan; Dan-dan Xu; Hai-xuan Chen; Xiao-yan Wang; Xiao Wang; Yu-ting Liu; Li Zhang; Sheng Wang; Peng-jun Zhou; Wu-yu Fu; Bi-bo Ruan; Dong-lei Ma; Ying Wang; Qiu-ying Liu; Zhe Ren; Zhong Liu; Rong Zhang; Yi-fei Wang
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379

View more
  2 in total

1.  Optimization of eIF4E-Binding Peptide Pep8 to Disrupt the RBM38-eIF4E Complex for Induction of p53 and Tumor Suppression.

Authors:  Christopher A Lucchesi; Jin Zhang; Demitria M Vasilatis; Elizabeth Yip; Xinbin Chen
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

2.  Estrogen receptor beta promotes lung cancer invasion via increasing CXCR4 expression.

Authors:  Shiqing Liu; Chengping Hu; Min Li; Jian An; Wolong Zhou; Jia Guo; Yao Xiao
Journal:  Cell Death Dis       Date:  2022-01-21       Impact factor: 9.685

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.